Up-regulation of inhibitors of DNA binding/differentiation gene during alendronate-induced osteoblast differentiation by Kang, Ae Ra et al.
GENERAL GYNECOLOGY
Up-regulation of inhibitors of DNA binding/differentiation gene
during alendronate-induced osteoblast differentiation
Ae Ra Kang • Young Rim Oh • Heung Yeol Kim • Min Jung Park •
Bo Sun Joo • Won Jun Choi • Ji Young Lee • Min Hyung Jung • Yong Il Ji •
Jong Soon Choi
Received: 8 August 2011/Accepted: 4 November 2011/Published online: 25 November 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Purpose To investigate the effect of alendronate on the
expression of Id genes in osteoblast differentiation.
Methods C2C12 cells were treated with alendronate for
various concentrations and time periods. For evaluation of
alendronate-induced osteoblast differentiation in C2C12
cells, alkaline phosphatase (ALP) activity was measured.
The expression of osteoblast differentiation markers such
as ALP, type-1 collagen (Col 1), and osteocalcin (OCN),
and the expression of Id-1 and Id-2 were measured by RT-
PCR. In order to understand the mechanism underlying the
regulation of Id genes, the promoter region of the Id-1 gene
was identiﬁed. Database analysis of the promoter region for
Id-1 using known consensus sequences identiﬁed several
putative response elements, including CCAAT/enhancer-
binding protein beta (C/EBPb).
Results Alendronate treatment signiﬁcantly increased not
only ALP activity but also the expression of ALP, Col 1,
and OCN, Id-1 and Id-2. C/EBPb and alendronate coop-
eratively increased the promoter activity and expression of
Id-1.
Conclusions These results suggest that C/EBPb-mediated
Id-1 transcriptional activation may regulate alendronate-
induced osteoblast differentiation of C2C12 cells.
Keywords Alendronate   Osteoblasts   Osteoporosis
Introduction
Bisphosphonates are commonly used in the treatment and
prevention of excessive bone resorption diseases such as
post-menopausal osteoporosis due to their inhibitory
osteoclast activity [1]. However, there has been increasing
evidence that a variety of bisphosphonates can also stim-
ulate osteoblast proliferation, differentiation, and bone
formation, as well as inhibit osteoblast apoptosis [2–5].
The process of osteoblast differentiation is under various
central and local controls including bone morphogenetic
proteins (BMP), Indian hedgehog, ﬁbroblast growth factor-
2 (FGF2), Wnt, parathyroid hormone, and leptin [6–9]. Fur-
ther, studies have proposed several possible mechanisms
governingbisphosphonate-mediatedosteoblastdifferentiation
[10, 11].
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DOI 10.1007/s00404-011-2141-1Inhibitors of DNA binding/differentiation (Id), which
are inhibitory helix–loop–helix (HLH) transcription fac-
tors, have been reported to affect the balance between cell
growth and differentiation of osteoblast [12, 13]. Further, it
has been indicated that a balanced regulation of Id gene
expression plays an important role in promoting prolifer-
ation at the early stage of osteoblast lineage-speciﬁc dif-
ferentiation [12]. Bone morphogenetic proteins (BMPs) are
known to convert the differentiation pathway of myoblastic
cell lines into osteoblast lineages and stimulate osteoblast
lineage-speciﬁc differentiation of mesenchymal stem cells
by controlling expression of inhibitors of DNA binding/
differentiation (Ids) [6, 12].
Alendronate, which is a well-known third-generation
bisphosphonate, enhances the expression of BMP-2 and
osteoblast maturation [4]. However, no studies to date have
evaluated the possible role of Ids in alendronate-induced
osteoblast differentiation. Therefore, the purpose of this
study was to investigate the expression of Ids genes in
alendronate-induced osteoblast differentiation using myo-
blastic C2C12 cells.
Materials and methods
Cell culture and alendronate treatment
C2C12 cells were maintained under 5% CO2 at 37Ci n
growth medium, consisting of Dulbecco’s modiﬁed Eagle’s
medium (DMEM; Gibco BRL, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (FBS; Gibco
BRL) and 1% penicillin–streptomycin (PS; Gibco BRL).
The medium was changed every 2 or 3 days, and the cells




C2C12 cells were plated at a density of 2 9 10
4 cells in
24-well plates. After overnight incubation, alendronate was
added to ﬁnal concentrations ranging from 10
-3 to 10
-9 M
for 24, 48, and 72 h. At the time points indicated, the cells
were washed with PBS, and 100 ll of MTT stock solution
(5 mg/ml, Sigma, St. Louis, MO, USA) was added to each
culture medium and continued for 1 h at 37C. This time
period permitted the cellular conversion of MTT to an
insoluble form. Then, the cells were lysed, and the for-
mazan crystals were dissolved in DMSO at room temper-
ature for 5 min, after which 100 ll of supernatant was
transferred to the wells of a 96-well microplate. Colori-
metric changes were subsequently quantiﬁed using a
microplate reader at a wavelength of 540 nm (Spectra
MAX 250, Molecular Devices Co., USA).
Alkaline phosphatase activity assay
To mediate the differentiation of C2C12 cells to osteo-
blasts, C2C12 cells were ﬁrst plated at a density of 2 9 10
4
cells in 24-well plates. After overnight incubation, the cells
were cultured in serum-free DMEM with or without
alendronate at concentrations ranging from 10
-4 to 10
-9 M
for 24, 48, and 72 h. At the time points indicated, the cells
were washed with ice-cold phosphate-buffered saline
(PBS), lysed in 1% Triton X-100 (Sigma), and subjected to
three freeze–thaw cycles. After centrifugation (4,000g)o f
the lysates, the cellular debris were removed and super-
natants were collected. The collected supernatants were
then mixed with a colorless p-nitrophenyl phosphate
(Sigma) according to the manufacturer’s protocol, and the
conversion of colored p-nitrophenol was measured using a
microplate reader at a wavelength of 405 nm.
RNA preparation and RT-PCR
Quantitative RT-PCR conditions were set for analysis of
three osteoblast differentiation markers, namely, alkaline
phosphatase activity (ALP), type-1 collagen (Col 1) and
osteocaclin (OCN). Total RNA was extracted using Trizol
reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s protocol. Complementary DNA was syn-
thesized from 5 lg of total RNA with AMV Reverse
Transcriptase (Promega, Madison, WI, USA) using random
hexamers (Bioneer, Daejon, Korea) at 42C for 1 h. Tem-
plate cDNA was subjected toPCR ampliﬁcation usinggene-
speciﬁc sense and antisense primers (Table 1). The cDNAs
were ampliﬁed by PCR under the following conditions:
28–35 cycles of denaturation at 95C for 30 s, annealing at
58C for 30 s, and extension at 72C for 30 s in a thermal
cycler. PCR products were visualized by electrophoresis on
1.2% agarose gels. The PCR bands were quantiﬁed and
normalizedrelativetothecontrolbandwithImageJ,version
1.35d (National Institutes of Health Image software).
Transient transfection of C2C12 cells and luciferase
activity assay
C2C12 cells were plated in 24-well plates 1 day before
transfection. The cells were transiently transfected with a
reportervectorandb-galactosidaseexpressionplasmid,along
with each indicated expression plasmids using Jetpei (poly-
plus-transfection, Illkirch, France); addition of pcDNA3.1/
HisC plasmid DNA was added to maintain equal amounts of
DNA per transfection. After 48 h post-transfection, the cells
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Lysis Buffer (Promega). Luciferase activity was determined
using an analytical-luminescence luminometer according to
the manufacturer’s instructions. Luciferase activity was nor-
malized for transfection efﬁciency according to the corre-
sponding b-galactosidase activity.
Statistical analysis
All experiments were performed at least ﬁve times, and the
data are expressed as the mean ± SD. The statistical sig-
niﬁcance of differences between the experiment and con-
trol groups were evaluated by student’s t test and one-way
ANOVA. Values of P\0.05 were considered to be sta-
tistically signiﬁcant.
Results
Effect of alendronate on cell viability and ALP activity
in C2C12 cells
There were no signiﬁcant changes in the percentage of
viable cells at concentrations of alendronate ranging from
10
-4 to 10
-9 M up to 72 h. However, cell viability was
signiﬁcantly decreased with a higher dose (10
-3 M) of
alendronate (Fig. 1). Based on the results of this viability
assay, we assessed osteoblast differentiation by measuring




osteoblast differentiation of C2C12 cells increased nearly
twofold as determined by ALP activity in response to all
concentrations of alendronate after 24 h of treatment
compared to the control group. Furthermore, elevated ALP
activity was also observed at alendronate concentrations
from 10
-6 to 10
-8 M for 48 h (Fig. 2). Together, these
results suggested that alendronate might play a role in the
early stage of C2C12 cell differentiation into osteoblasts.
Effect of alendronate on osteoblast-speciﬁc gene
expression
To clarify the potential role of alendronate in osteoblast dif-
ferentiationofC2C12cells,wenextexaminedtheexpression
of three osteoblast-speciﬁc genes, namely, ALP, Col 1, and
OCN. For these experiments, C2C12 cells were treated with
alendronate at concentrations ranging from 10
-6 to 10
-8 M
for 48 h based on the ALP activity assays. Treatment with
alendronate treatment resulted in a signiﬁcant increase in
expression of ALP, Col 1, and OCN compared to controls.
Further, the expression levels of ALP and Col 1 peaked at an
alendronate concentration of 10
-8 M (Fig. 3a, b).
Following the treatment with 10
-8 M of alendronate,
the concentration of which resulted in peak levels of ALP
and Col 1, C2C12 cells were treated with alendronate of
10
-8 M for 24, 48, and 72 h to evaluate the effect of
alendronate according to treatment time. The time course
study indicated that the expression of ALP and Col 1 was
signiﬁcantly increased until 48 h, but decreased thereafter.
Likewise, the expression of OCN was signiﬁcantly
increased from 72 h (Fig. 3c, d). These results indicate the
Table 1 Primers sequences used for PCR ampliﬁcation
Gene Primer sequence
Alkaline phosphatase (ALP)
Forward 50- TCATGTTCCTGGGAGATTGGGTATG -30
Reverse 50- GCATTAGCTGATAGGCGATGTCC -30
Type I Collagen (Col 1)
Forward 50- CAAGGGTGAGACAGGGCAAC -30
Reverse 50- CTCGAACTGGAATCCATCGGT -30
Osteocalcin (OCN)
Forward 50- CTGAGTCTGACAAAGCCTTC -30
Reverse 50- GCTGCTGTGACATCCATACTTGC -30
Cathepsin K (CTSK)
Forward 50- GGGCCAGGATGAAAGTTGTA -30
Reverse 50- CCGAGCCAAGAGAGCATATC - 30
Inhibitor of differentiation-1 (Id1)
Forward 50- CTGCTCTACGACATGAACGGCTG -30
Reverse 50- CGGATTCCGAGTTCAGCTCCAAC - 30
Inhibitor of differentiation-2 (Id2)
Forward 50- GGGCCAGGATGAAAGTTGTA -30
Reverse 50- CCGAGCCAAGAGAGCATATC -30
b-Actin
Forward 50- GACTACCTCATGAAGATC -30
Reverse 50- GATCCACATCTGCTGGAA -30
Fig. 1 Effect of alendronate on cell viability. C2C12 cells were
treated with alendronate using concentrations ranging from 10
-3 to
10
-9 M for 24, 48, and 72 h. Cell viability was determined using
MTT assay (mean ± SD, n = 5)
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123presence of different expression patterns for each osteo-
blast-speciﬁc marker according to the concentration and
duration of alendronate treatment in alendronate-induced
osteoblast differentiation.
Expression of Id-1 and Id-2 during alendronate-induced
osteoblast differentiation of C2C12 cells
Next, we carried out expression analysis of Id genes in
alendronate-induced osteoblast differentiated C2C12 cells.
Alendronate treatment signiﬁcantly stimulated Id-1 and Id-
2 mRNA expression at all treated doses compared to
controls (Fig. 4a, b).
We further examined the expression of Id-1 and Id-2 at
24, 48, and 72 h after treatment with alendronate at con-
centration of 10
-8 M based on above data. Alendronate
treatment exhibited a signiﬁcant increase in the expression
of both Id-1 and Id-2 genes compared to controls. The
expression of Id-1 was signiﬁcantly increased after
alendronate treatment at all time-periods, although levels
peaked at 48 h. Similarly, Id-2 expression was signiﬁcantly
up-regulated until 48 h, but was undetectable thereafter
(Fig. 4c, d). These results indicated that Id-1 and Id-2
might be involved in alendronate-induced early stage of
osteoblast differentiation in C2C12 cells.
Effect of alendronate on C/EBPb-mediated Id-1
transcriptional activity
In order to investigate the transcriptional mechanism by
which alendronate regulates the expression of Id-1, we
examined the promoter region of the Id-1 gene using the
GeneBank database to search for known consensus sequen-
cesintheId-1promoter.Severalputativeresponseelements,
suchasNuclearfactor-kappaB(NF-kB),acutemyelogenous
leukemia1/runt-related transcription factor1 (AML1/
RUNX1), CDX, cAMP response element binding (CREB),
and CCAAT/enhancer-binding protein beta (C/EBPb) were
detected in the Id-1 promoter region. C2C12 cells were
transiently co-transfected with Id-1-luciferase reporter vec-
tor along with expression vector encoding these response
elements or empty vector. After transfection, Id-1 promoter
activity was signiﬁcantly increased in CREB or C/EBPb
overexpressing cells compared to controls. Especially,
C/EBPb induced approximately 4.3-fold increase in Id-1
promoter activity (Fig. 5a). To investigate whether C/EBPb
regulates the expression of Id-1 stimulated by alendronate,
C2C12 cells were co-transfected with the Id-1 luciferase
reporter plasmid along with C/EBPb-expression vector,
followed by alendronate treatment. Overexpression of
C/EBPbandalendronatetreatmentsynergisticallyincreased
Id-1 promoter activity (Fig. 5b).
In order to determine further the effect of alendronate-
induced osteoblast differentiation on C/EBPb-mediated Id-
1 expression, we transiently transfected the C/EBPb
expression vector or empty vector as a control in the
absence or presence of alendronate. Consistent with the
results of the reporter assay, expression of Id-1 was slightly
increased in the presence of C/EBPb. Overexpression of
C/EBPb and alendronate markedly increased ALP
expression in C2C12 cells (Fig. 5c, d). These results indi-
cated that alendronate increased ALP expression, a marker
of early osteoblast differentiation, and this increased
expression might be associated with increased Id-1
expression through transcriptional regulation of C/EBPb.
Discussion
The present study demonstrated that alendronate induced
osteoblast differentiation of the C2C12 myoblastic cell
line. This study also revealed an interesting ﬁnding
whereby alendronate stimulated the expression of Id genes,
which was accompanied by up-regulation of C/EBPb-
mediated Id-1 expression.
The expression of Id genes was signiﬁcantly increased
in the early stage of BMP stimulated-osteoblast differen-
tiation [12, 14]. Especially, BMP-2 stimulates not only
various osteoblast-speciﬁc differentiation markers, but also
converts the differentiation pathway of C2C12 myoblasts
into the osteoblast lineage [6, 8, 12]. Im et al [4] reported
that alendronate enhances the expression of BMP-2 in
osteoblasts. Such previous results imply that alendronate
might stimulate osteoblast differentiation by regulation of
Fig. 2 Effect of alendronate-induced osteoblast differentiation of
C2C12 cells. Cells were treated with alendronate at different
concentration and time periods as indicated. The ALP activity was
measured at 405 nm. The experiment was repeated ﬁve times and
performed with triple samples. *P\0.05 and **P\0.01 compared
(vs. control)
1334 Arch Gynecol Obstet (2012) 285:1331–1338
123Fig. 3 Effect of alendronate on the expression of osteoblast differ-
entiation markers. Osteoblast differentiation was determined by RT-
PCR analysis for the expression of ALP, and Col 1. C2C12 cells were
treated with alendronate at concentrations ranged from 10
-6 to
10
-8 M for 48 h (a) and at 10
-8 M concentration for different time
periods (24, 48, and 72 h) (c). Data are from a representative
experiment. b, d The amount of each mRNA was normalized to that
of b-actin mRNA. Quantitative data are means ± SD from six
independent experiments. *P\0.05, **P\0.01 and
#P\0.005 (vs.
control)
Fig. 4 Expression of Id-1 and Id-2 genes during alendronate-induced
osteoblast differentiation. C2C12 cells were treated with alendronate
at concentrations ranging from 10
-6 to 10
-8 M for 48 h (a) and at
10
-8 M concentration for different time periods (24, 48, and 72 h)
(c). At the indicated time after alendronate treatment, the expression
of Id-1 and Id-2 mRNA was analyzed by RT-PCR. Data are from a
representative experiment. b, d The amount of Id-1 and Id-2 mRNA
was normalized btoy that of b-actin mRNA. Quantitative data are
mean ± SD from six independent experiments. *P\0.05,
**P\0.01 and
#P\0.005 (vs. control)
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123Id gene expression. In our study, the expression of Id-1 and
Id-2 peaked within 48 h of alendronate-induced osteoblast
differentiation of C2C12 cells. In this respect, our results
suggest the possibility that alendronate might be associated
with the BMP-2 signaling pathway to induce osteoblast
differentiation. However, further study is needed to eval-
uate this hypothesis.
C/EBPs are critical for normal cellular differentiation
and metabolic functions in various tissues. Especially,
C/EBPb is expressed in osteoblastic cells and up-regulated
during osteoblast differentiation [15]. This result led us to
the hypothesis that increased expression of Id-1 by
alendronate might be mediated via a C/EBPb-binding
element contained within the Id-1 promoter. The present
study showed that overexpression of C/EBPb and alendr-
onate treatment synergistically increased the promoter
activity and expression of Id-1. To the best of our knowl-
edge, this is the ﬁrst study to report a potential role of Id-1
and C/EBPb in alendronate-induced differentiation of
C2C12 cells into osteoblasts.
We demonstrated the presence of differential patterns of
increased expression of Id-1 and Id-2 expression by
alendronate. This ﬁnding was not unexpected, as Id-1 is
known to be a direct target gene for BMPs that strongly
activate its promoter [16–19]. Although the exact mecha-
nism is unclear, induction of Id-2 in alendronate-induced
osteoblast differentiation of C2C12 cells might involve
indirect targeting of BMP-signaling.
In their study of alendronate localization in rat bones,
Sato et al. [20] reported that alendronate was accumulated
in the resorption space at a maximum concentration of
10
-3 M after alendronate injection. Consistent with the
results of our study, Garcia-Moreno et al. [2] showed that
no viable cells were detected with alendronate concentra-
tions of 10
-3 M or higher, while at lower concentrations of
alendronate, there were no signiﬁcant effects compared to
Fig. 5 Effect of alendronate on Id-1 transactivation. a Determination
of response elements in the Id-1 promoter region. C2C12 cells were
transiently transfected with Id-1-luciferase reporter vector along with
expression vector encoding p65, AML1a, CDX1, CDX2, CREB or
C/EBPb, or empty vector as control. After 48 h of transfection, cell
lysates were assayed for luciferase activity. Results are the average of
three independent experiments, with fold induction referring to the
level observed divided by the reporter activity alone. *\0.05 (vs.
empty vector). b The effect of alendronate on C/EBPb-mediated Id-1
transactivation. C2C12 cells were transiently transfected with Id-1-
luciferase reporter plasmid along with an expression vector encoding
for C/EBPb or an empty vector and then treated with 10
-8 Mo f
alendronate. After 48 h of transfection, cell lysates were assayed for
luciferase activity (upper panel) and subjected for expression of the
indicated transcripts by RT-PCR (lower panel). Bars represent the
mean ± SD of six independent experiments with duplication.*\0.05
(vs. empty vector) and
#\0.005 (vs. C/EBPb alone). c C2C12 cells
were transiently transfected with expression vector pcDNA3 alone
(empty vector) or containing C/EBPb expression vector and then
treated with 10
-8 M of alendronate. The Id-1 and ALP mRNA levels
were detected via RT–PCR (left panel). The amount of each mRNA
was normalized to that of b-actin mRNA (right panel). Experiments
were performed at least ﬁve times; representative experiments are
shown.
#\0.005 (vs. control)
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greatly dose-dependent in a rat model of arthritis; high
doses of alendronate have an adverse effect on osteoblast
Function [20]. This dose dependent effect of alendronate
was also supported by previous studies showing that bis-
phosphonates increase bone marrow-derived preosteoblas-
tic cell proliferation and inhibit the apoptosis of osteocytes
and osteoblasts at low concentrations [3, 21]. This dose-
dependent effect was also observed in our present study,
which showed that low concentrations of alendronate
stimulated early signs of osteoblast differentiation such as
increased ALP activity. Thus, it can be concluded that low
doses of alendronate may stimulate osteoblast differentia-
tion of C2C12 cells, whereas a higher dose may inhibit
osteoblast function.
The present study shows that the expression pattern of
each osteoblast marker differed according to the time
periods of alendronate treatment; ALP and Col1 expression
increased up to 48 h, but decreased thereafter, whereas
OCN expression was increased only after 48 h. This result
may be attributable to the fact that each osteoblast differ-
entiation marker reﬂects different stages of differentiation
and thus different osteoblastic activity; ALP and Col 1 are
early markers of osteoblast differentiation, while OCN
appears late, concomitant with mineralization [6, 22].
In this present study, gene expression at the mRNA level
was evaluated but expression at the protein level was not.
This would be the limitation of this study. Despite the
limitations of our study, the presented data may contribute
to the understanding of the mechanism of alendronate-
induced osteoblast differentiation, suggesting that alendr-
onate might initially promote the gene expression of
C/EBPb-mediated Id-1 and trigger the sequential activation
of osteoblast-speciﬁc genes such as ALP, Col 1, and OCN.
Differentiation processes are associated with morpho-
logical changes. Nakashima et al. [23] reported that the
transformed cell (Wnt3a-C2C12) exhibited a distinct
morphological change along with osteoblast gene expres-
sion. However, our present study could not observe mor-
phological changes of the C2C12 cells during the 3 days of
culture. This may be due to short culture duration. Naka-
shima et al. cultured transformed (Wnt3a-C2C12) cells for
3–9 days, and morphological changes were found at the 6th
day of culture. Therefore, to warrant our data, further
studies on the observation of morphological changes at the
protein level are needed, using stable Id-1 transformed
C2C12 cells for long-term culture.
In conclusion, the present study shows that the expres-
sion of Id-1 and Id-2 genes was stimulated in alendronate-
induced differentiation of C2C12 cells myoblasts into
osteoblast lineage. In addition, this study suggests that the
increased expression of Id-1 in alendronate-induced
osteoblast differentiation may be regulated by C/EBPb.
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